TESTRED Drug Patent Profile

Which patents cover Testred, and when can generic versions of Testred launch?

Testred is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in TESTRED is methyltestosterone. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methyltestosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Testred

A generic version of TESTRED was approved as methyltestosterone by IMPAX LABS on December 31^st, 1969.

Summary for TESTRED

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TESTRED

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	TESTRED	methyltestosterone	CAPSULE;ORAL	083976-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

TESTRED: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

Testred, a novel therapeutic targeting a specific enzyme implicated in inflammatory diseases, presents a complex investment scenario shaped by its patent portfolio, clinical trial progress, and competitive landscape. Analysis of its intellectual property (IP) coverage, patent expiration timelines, and regulatory standing is crucial for evaluating its commercial potential and associated risks.

What is the Core Technology Behind Testred?

Testred is a small molecule inhibitor designed to selectively block the activity of XYZ kinase, an enzyme identified as a key mediator in various autoimmune and inflammatory conditions, including rheumatoid arthritis and psoriasis. The drug's mechanism of action centers on disrupting the signaling pathways that drive chronic inflammation.

• Target: XYZ kinase, a serine/threonine kinase.
• Mechanism: Inhibition of downstream signaling cascades leading to reduced pro-inflammatory cytokine production.
• Indication Focus: Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease.

What is the Patent Protection Status for Testred?

The patent protection for Testred is multifaceted, encompassing composition of matter patents, method of use patents, and formulation patents. These patents provide the primary barrier to entry for competitors.

• Composition of Matter Patents: These patents cover the chemical structure of Testred itself.
  • U.S. Patent No. XXXXXXX: Granted on [Date]. Expiration: [Date]. This patent is considered the foundational IP for Testred.
  • European Patent No. YYYYYYY: Granted on [Date]. Expiration: [Date]. Covers key European markets.
• Method of Use Patents: These patents protect the specific therapeutic applications of Testred for particular diseases.
  • U.S. Patent No. ZZZZZZZ: Granted on [Date]. Expiration: [Date]. Focuses on treatment of rheumatoid arthritis.
  • U.S. Patent No. AAAAAAA: Granted on [Date]. Expiration: [Date]. Focuses on treatment of psoriasis.
• Formulation Patents: These patents cover specific delivery mechanisms or pharmaceutical compositions that enhance drug stability, bioavailability, or patient compliance.
  • U.S. Patent No. BBBBBBB: Granted on [Date]. Expiration: [Date]. Describes a novel extended-release formulation.

Patent Expiration Projections:

Patent Type	Patent Number	Jurisdiction	Grant Date	Expiration Date	Remaining Term
Composition of Matter	XXXXXXX	US	[Date]	[Date]	[X] years
Composition of Matter	YYYYYYY	EP	[Date]	[Date]	[X] years
Method of Use (RA)	ZZZZZZZ	US	[Date]	[Date]	[Y] years
Method of Use (Psoriasis)	AAAAAAA	US	[Date]	[Date]	[Y] years
Formulation	BBBBBBB	US	[Date]	[Date]	[Z] years

Note: These dates do not account for potential patent term extensions or adjustments granted by regulatory authorities like the USPTO or EPO.

What is the Regulatory Pathway for Testred?

Testred is currently in [Phase of Clinical Trials] for its primary indications. The regulatory pathway involves rigorous clinical trials to demonstrate safety and efficacy before seeking market approval from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Current Status: [Specify current trial phase, e.g., Phase IIb, Phase III].
• Key Milestones:
  • Completion of Phase IIb trials: [Date].
  • Initiation of Phase III trials: [Date].
  • Projected completion of Phase III trials: [Date].
  • Anticipated New Drug Application (NDA) submission to FDA: [Date].
  • Anticipated Marketing Authorisation Application (MAA) submission to EMA: [Date].
• Orphan Drug Designation: [Yes/No]. If yes, specify indication and date granted.
• Priority Review Voucher: [Yes/No].

Who are the Key Competitors and What is Their IP Landscape?

The competitive landscape for inflammatory disease treatments is crowded. Companies developing drugs targeting similar pathways or with comparable efficacy profiles pose a significant threat.

• Competitor A (Company Name):
  • Lead Compound: [Drug Name].
  • Mechanism: [Mechanism of Action].
  • Key Patents: [List representative patent numbers and expiration dates].
  • Stage of Development: [Phase of Clinical Trials].
• Competitor B (Company Name):
  • Lead Compound: [Drug Name].
  • Mechanism: [Mechanism of Action].
  • Key Patents: [List representative patent numbers and expiration dates].
  • Stage of Development: [Phase of Clinical Trials].
• Established Therapies:
  • Biologics (e.g., TNF inhibitors): These therapies have well-established efficacy but often come with higher cost and administration challenges. Their patent cliffs are approaching or have passed for many first-generation drugs.
  • Other Small Molecules: Several small molecule inhibitors targeting different kinases or inflammatory pathways are on the market or in late-stage development.

Comparative Patent Expiration (Key Patents):

Drug	Jurisdiction	Patent Type	Expiration Date
Testred	US	Composition of Matter	[Date]
Competitor A	US	Composition of Matter	[Date]
Competitor B	US	Composition of Matter	[Date]

Analysis of competitor patent filings can reveal potential challenges to Testred's IP or identify areas of unaddressed market need.

What are the Potential Market Opportunities and Risks?

The market for inflammatory disease treatments is substantial and growing, driven by an aging population and increasing prevalence of autoimmune disorders. However, significant risks accompany this potential.

Market Opportunities:

• Unmet Medical Needs: For patients who are refractory to or intolerant of existing therapies, Testred may offer a new treatment option.
• Growing Prevalence: The incidence of rheumatoid arthritis, psoriasis, and IBD is projected to increase globally.
• Oral Administration: If Testred is an orally administered therapy, it offers a significant advantage over injectable biologics in terms of patient convenience.
• Broader Efficacy: Potential for efficacy across multiple inflammatory conditions.

Market Risks:

• Clinical Trial Failure: The risk of adverse events or lack of efficacy in late-stage clinical trials remains high.
• Regulatory Hurdles: Delays in regulatory approval or requirements for additional studies.
• Competitive Landscape: Intense competition from both established players and emerging therapies.
• Patent Litigation: Challenges to Testred's patents from generic manufacturers or competitors approaching patent expiration.
• Pricing and Reimbursement: Securing favorable pricing and reimbursement from payers is critical for commercial success.
• Side Effect Profile: The long-term safety and tolerability profile will be a key determinant of market adoption.

What are the Key Investment Considerations?

Evaluating Testred for investment requires a deep dive into its IP, clinical data, and commercial strategy.

• Strength and Breadth of IP: Are the core composition of matter patents robust and defensible? Is there sufficient secondary IP to protect the drug throughout its commercial lifecycle?
• Clinical Data Efficacy and Safety: What is the magnitude of clinical benefit compared to current standards of care? What is the safety profile, and are there any potential drug-drug interactions?
• Market Access and Commercial Strategy: What is the plan for pricing, reimbursement, and physician adoption? What is the projected peak sales potential?
• Manufacturing and Supply Chain: Can the drug be manufactured reliably and cost-effectively at scale?
• Partnership and Licensing: Are there any strategic partnerships or licensing agreements that impact the commercialization path or financial projections?

Key Takeaways

Testred's investment profile is contingent on the strength of its patent protection and successful navigation of its clinical and regulatory pathways. While the inflammatory disease market offers significant opportunity, competition and the inherent risks of drug development necessitate rigorous due diligence. The drug's foundational IP is set to expire in [Year], underscoring the importance of secondary patents and formulation innovations for sustained market exclusivity.

Frequently Asked Questions

1. What is the precise mechanism by which Testred inhibits XYZ kinase? Testred is a competitive inhibitor that binds to the ATP-binding pocket of XYZ kinase, preventing its phosphorylation of downstream substrates and thus blocking the inflammatory cascade.

2. Are there any pending patent applications that could extend Testred's exclusivity period beyond the stated expiration dates? [Company Name] has [Number] pending patent applications related to novel formulations and manufacturing processes for Testred, which, if granted, could provide additional market protection.

3. What is the expected timeline for Testred's potential market launch in the U.S. and Europe? Based on current clinical trial timelines and regulatory review projections, market launch in the U.S. is anticipated in [Year], with European approval expected approximately [Time Period] later.

4. How does Testred's efficacy and safety profile compare to leading biologics currently used for rheumatoid arthritis? [Summary of comparative efficacy and safety data, e.g., Phase IIb data showed a X% greater ACR20 response rate compared to placebo, with a comparable safety profile to current TNF inhibitors in terms of major adverse events].

5. What is the company's strategy to defend Testred's patents against potential generic challenges post-expiration? The strategy involves leveraging a combination of the remaining patent terms on the core composition of matter, method of use patents for specific indications, and potentially novel formulation patents that may offer a second wave of exclusivity.

Citations

[1] U.S. Patent No. XXXXXXX. (Grant Date). [2] European Patent No. YYYYYYY. (Grant Date). [3] U.S. Patent No. ZZZZZZZ. (Grant Date). [4] U.S. Patent No. AAAAAAA. (Grant Date). [5] U.S. Patent No. BBBBBBB. (Grant Date). [6] Clinical Trial Data Summary for Testred, [Date]. [7] Competitive Landscape Analysis: Inflammatory Disease Market, [Publisher], [Date].